Symbolbild · KI-generiert
Upstream Bio, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
Upstream Bio is a clinical-stage biotechnology company developing therapies for inflammatory respiratory diseases. Its lead candidate Verekitug is an antibody targeting the TSLP receptor, being investigated in severe asthma and other eosinophilic conditions. The company is in the clinical development stage.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Upstream Bio, Inc. | UPB | NASDAQ | 343 Mio. USD |
| TECSYS Inc. | TCS | TSX | 344 Mio. USD |
| Compass Therapeutics, Inc. | CMPX | NASDAQ | 344 Mio. USD |
| Carlsmed, Inc. | CARL | NASDAQ | 342 Mio. USD |
| DiaMedica Therapeutics Inc. | DMAC | NASDAQ | 342 Mio. USD |
| Fennec Pharmaceuticals Inc. | FRX | TSX | 346 Mio. USD |
| Standard BioTools Inc. | LAB | NASDAQ | 340 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.